Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 12, 2021, titled "Alembic Pharmaceuticals announces its wholly-owned subsidiary, Alembic Global Holding SA, receives USFDA Final Approval for Treprostinil Injection, 20 mg/20 mL (1 mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), Multiple-Dose Vials".